Find more information about Teva in your location, or contact a local representative on our local sites
North America
International Markets
North America
Toggle North America
International Markets
Toggle International Markets
Europe
Toggle Europe
Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia
- Study Title
- A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia
- Teva Identifier
- TV44749-BA-10196
- ClinicalTrials.gov Identifier
- NCT06315283
- Study Status
- Recruiting
- Trial Condition(s)
- Schizophrenia
- Interventions
- Drug: TV-44749
- EudraCT Number
- 2023-505664-11-00
Study Description
The primary objective of the study is to evaluate the comparative bioavailability of TV-44749 administered subcutaneous (sc) to oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia.
Key Participation Requirements
- Gender
- Female, Male
- Age Range
- 18 Years to 64 Years
- Trial Duration
- March 20, 2024 - April 18, 2025
- Phase
- Phase 1
